CancerDrs

Colorectal Cancer clinical trials in Rhode Island

7 actively recruiting colorectal cancer trials at 1 site across Rhode Island.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Industry

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Tr…

Sponsor: Summit Therapeutics
NCT ID: NCT07228832
Sites in Rhode Island:
  • Clinical Study Site — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the P…

Sponsor: 7 Hills Pharma, LLC
NCT ID: NCT06362369
Sites in Rhode Island:
  • Brown University Health Cancer Institute — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have be…

Sponsor: Brown University
NCT ID: NCT06555133
Sites in Rhode Island:
  • Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Providence, Rhode Island, United States, 02903 Contact: — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driv…

Sponsor: Bicara Therapeutics
NCT ID: NCT04429542
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

TLR9 Immunotherapy for Peritoneal Carcinomatosis

The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites. The main questions it aims to answer are: • To determine the safety and maximum tolerated dose…

Sponsor: Brown University
NCT ID: NCT07658196
Sites in Rhode Island:
  • Rhode Island and the Miriam Hospitals (Brown University Health) — Providence, Rhode Island
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Rhode Island:
  • Massive Bio SYNERGY-AI site — Providence, Rhode Island
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12